openPR Logo
Press release

Osteoarthritis Market Competitive And Growth Analysis 2024 | Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Abbvie Inc., Bayer AG, Novartis AG

08-12-2024 09:26 AM CET | Health & Medicine

Press release from: The Business Research Company

Osteoarthritis Global Market Report 2024

Osteoarthritis Global Market Report 2024

"The new report published by The Business Research Company, titled Osteoarthritis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the osteoarthritis market size has grown rapidly in recent years. It will grow from $6.24 billion in 2023 to $6.87 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The osteoarthritis market size is expected to see strong growth in the next few years. It will grow to $9.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13022&type=smp

Rising Obesity-Related Disorders Fuel Growth In The Osteoarthritis Market
The increasing obesity-related disorders are expected to boost the growth of the osteoarthritis market going forward. Obesity-related problems refer to a range of health issues that can arise from excessive body fat. It is caused by consuming more calories than the body burns through physical activity and exercise, eating large amounts of processed or fast food and drinking too much alcohol. Obesity can induce osteoarthritis by putting strain on joints, producing inflammation and altering hormones, thus increasing the load on the joints. For instance, according to the World Obesity Atlas 2022, published by the World Obesity Federation, a UK-based non-profit organization, 1 billion people worldwide, including 1 in 7 men and 1 in 5 women, will be living with obesity by 2030 and it will increase to 4 billion people or 51% of the global population, will be living either overweight or obese by 2035. Therefore, the increasing obesity-related disorders are driving the growth of the osteoarthritis market.

Innovative Approaches And Advanced Treatments Transform The Osteoarthritis Market
Major companies operating in the osteoarthritis market are focusing on developing new products and advanced treatment drugs, such as small molecule inhibitors, intra-articular injections of hyaluronic acid and single injection viscosupplement, to sustain their market position. For instance, in August 2021, Seikagaku Corporation, a Japan-based pharmaceutical and medical device company, launched HyLink, a single-injection viscosupplement administered intra-particularly for treating knee osteoarthritis. The primary component of this product is crosslinked hyaluronate hydrogel, which was manufactured using Seikagaku's exclusive crosslinking technique. HyLink is anticipated to provide long-lasting relief from symptoms with only a 3ml dosage since the highly viscoelastic hyaluronate hydrogel stays in the knee joint cavity for a considerable time to improve lubrication and reduce pain.

The osteoarthritis market covered in this report is segmented -

1) By Treatment: Medication; Surgery; Therapy
2) By Diagnosis: Imaging; Joint Fluid Analysis
3) By Route Of Administration: Parenteral Route; Topical Route; Oral Route
4) By Disease Type: Knee Osteoarthritis; Spine Osteoarthritis; Foot And Ankle Osteoarthritis; Shoulder Osteoarthritis; Hand Osteoarthritis
5) By End-User: Hospitals; Medical Institutes

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13022&type=discount

Major players in the osteoarthritis market are Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Abbvie Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories Incorporation, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Zimmer Biomet Holdings Inc., Eisai Co. Ltd., Horizon Therapeutics PLC, Apotex Inc., Mallinckrodt Pharmaceuticals, Pacira BioSciences Inc., Bioventus Inc., Endo Pharmaceuticals Inc., Assertio Therapeutics Inc., Anika Therapeutics Inc., Abiogen Pharma Spa, Kolon TissueGene Inc., Ampio Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Osteoarthritis Market Report Structure
3. Osteoarthritis Market Trends And Strategies
4. Osteoarthritis Market - Macro Economic Scenario
5. Osteoarthritis Market Size And Growth
…..
27. Osteoarthritis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Osteoarthritis Market Competitive And Growth Analysis 2024 | Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Abbvie Inc., Bayer AG, Novartis AG here

News-ID: 3619009 • Views:

More Releases from The Business Research Company

Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by 2029
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide. Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025? Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billion by 2029
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports. What is the Projected Market Size of the Rheology Modifiers Industry? There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analysis Report
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide. Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025? In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growth at 7.1% CAGR Forecast
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports. What is the Projected Market Size of the Pharmaceutical Intermediates Industry? There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound

All 5 Releases


More Releases for Osteoarthritis

Osteoarthritis Market Massive Growth opportunity Ahead
Introduction Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation. According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025? In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across
Osteoarthritis Treatment Market
Introduction Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779 This latest report researches the industry structure, sales, revenue,
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market. What the Osteoarthritis Therapeutics Market Looks Like? The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8